Skip to main content

Table 3 Results of the hierarchical regression analysis for hostility and defensiveness predicting telomere length in the patient groups

From: The associations of hostility and defensiveness with telomere length are influenced by sex and health status

   

β

t

p

Semipartial r

95% CI

Regression 1

 BLOCK 1

  Age

− 0.24

− 6.86

0.006*

− 0.21

[− 0.002, − 0.001]

  Sex

0.05

1.40

0.16

0.04

[− 0.002, − 0.011]

  CAD status

0.03

0.83

0.41

0.03

[− 0.004, 0.009]

  Employment status

− 0.01

− 0.36

0.72

− 0.01

[− 0.008, 0.005]

  #Cigarettes daily

− 0.03

− 1.13

0.26

− 0.03

[− 0.001, 0.000]

  #Exercise hours/week

0.06

1.90

0.06

0.06

[0.000, − 0.001]

  #Alcohol beverages/week

− 0.07

− 2.10

0.04

− 0.06

[− 0.001, − 0.002]

  Waist circumference

− 0.03

− 0.99

0.32

− 0.03

[0.000, − 0.000]

  Glucose

− 0.01

− 0.32

0.75

0.01

[− 0.002, 0.002]

  Mean arterial pressure

0.08

2.65

0.008*

0.08

[0.000, 0.000]

  Cholesterol total

0.05

1.40

0.16

0.08

[− 0.001, 0.005]

  History of CVD risk

− 0.04

− 1.02

0.31

− 0.03

[− 0.014, 0.004]

  F(12,1023) = 11.08, p < 0.001, R2 = 0.115, R2adj = .105

 BLOCK 2

  Hostility

− 0.03

− 0.91

0.37

− 0.03

[− 0.001, 0.000]

  F (1, 1022) = 0.82, p = 0.37, i2 = 0.116, R2adj = 0.104

 BLOCK 3

  Hostility*sex

− 0.08

− 2.78

0.006*

− 0.08

[− 0.002, − 0.0003]

  F(1,102) = 7.72, p = 0.007, R2 = 0.122, R2adj = 0.110

Regression 2

 BLOCK 2

  Defensiveness

0.03

0.84

0.40

0.03

[− 0.001, 0.001]

  F (1, 1022) = 0.71, p = 0.40, R2 = 0.116, R2adj = 0.104

  

 BLOCK 3

  Defensiveness*CAD status

− 0.06

− 1.98

0.049*

− 0.058

[− 0.004, − 0.000]

  F(1,1021) = 3.90, p = 0.007, R = 0.119, R2adj = 0.107

  1. CI: confidence interval
  2. CAD status (dichotomized)= with (1) or without CAD (2); Employment status (dichotomized) = retired or non-employed (1), full-time or part-time (2). History of CVD risk (dichotomized) = absence (0) or presence (1) of hypertension (and/or) diabetes (and/or) hypercholesterolemia and CVD agents (e.g., dyslipidemic, antihypertensive agents, insulin, oral hyperglycemics)
  3. *p < .05
  4. #: Number of